ZLD1039（Cat No.:I010048）is a potent and selective inhibitor of enhancer of zeste homolog 2 (EZH2), a histone methyltransferase responsible for tri-methylation of lysine 27 on histone H3 (H3K27me3), a mark associated with gene silencing. By selectively targeting EZH2, ZLD1039 effectively reduces H3K27me3 levels, reactivating silenced tumor suppressor genes and inhibiting cancer cell proliferation. It demonstrates significant anti-tumor activity, particularly in cancers driven by EZH2 mutations or overexpression, such as lymphoma and certain solid tumors. Thus, ZLD1039 serves as a valuable research tool for exploring epigenetic regulation mechanisms and developing targeted cancer therapies.